Based on the Danaher Corporation stock forecast from 17 analysts, the average analyst target price for Danaher Corporation is USD 277.62 over the next 12 months. Danaher Corporation’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Danaher Corporation is Slightly Bearish, which is based on 5 positive signals and 8 negative signals. At the last closing, Danaher Corporation’s stock price was USD 210.23. Danaher Corporation’s stock price has changed by +1.90% over the past week, -13.90% over the past month and -17.18% over the last year.
No recent analyst target price found for Danaher Corporation
No recent average analyst rating found for Danaher Corporation
Company Overview Danaher Corporation
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia. Read Less
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development a...Read More
Frequently Asked Questions About Danaher Corporation (DHR) Stock
Based on ratings from 17 analysts Danaher Corporation's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 21 buy, sell and 8 hold ratings.
DHR stock's dividend yield is 0.48%.
Our analysis grades DHR stock's dividend yield at F. This means that DHR stock's dividend yield is above 17% of the stocks in the Diagnostics & Research sector in the NYE exchange.
Based on this DHR may be a poor dividend stock for its sector.
Based on targets from 17 analysts, the average taret price for DHR is USD 277.62 over the next 12 months. The maximum analyst target price is USD 315 while the minimum anlayst target price is USD 240.
DHR stock's Price/Earning ratio is 39.09.
Our analysis grades DHR stock's Price / Earning ratio at F. This means that DHR stock's Price/Earning ratio is above 62% of the stocks in the Diagnostics & Research sector in the NYE exchange.
Based on this DHR may be a overvalued for its sector.
The last closing price of DHR's stock was USD 210.23.
The most recent market capitalization for DHR is USD 148.68B.
Based on targets from 17 analysts, the average taret price for DHR is projected at USD 277.62 over the next 12 months.
This means that DHR's stock price may go up by +32.06% over the next 12 months.
We can't find any ETFs which contains Danaher Corporation's stock.
As per our most recent records Danaher Corporation has 61,000 Employees.
Danaher Corporation's registered address is 2200 Pennsylvania Avenue, North West, Washington, DC, United States, 20037-1701.
You can get more information about it from Danaher Corporation's website at https://www.danaher.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Dividend Growth
This stock has shown top quartile dividend growth in the previous 5 years compared to its sector
What not to like
Poor return on assets
The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Danaher Corporation (DHR) Stock
Based on ratings from 17 analysts Danaher Corporation's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 21 buy, sell and 8 hold ratings.
DHR stock's dividend yield is 0.48%.
Our analysis grades DHR stock's dividend yield at F. This means that DHR stock's dividend yield is above 17% of the stocks in the Diagnostics & Research sector in the NYE exchange.
Based on this DHR may be a poor dividend stock for its sector.
Based on targets from 17 analysts, the average taret price for DHR is USD 277.62 over the next 12 months. The maximum analyst target price is USD 315 while the minimum anlayst target price is USD 240.
DHR stock's Price/Earning ratio is 39.09.
Our analysis grades DHR stock's Price / Earning ratio at F. This means that DHR stock's Price/Earning ratio is above 62% of the stocks in the Diagnostics & Research sector in the NYE exchange.
Based on this DHR may be a overvalued for its sector.
The last closing price of DHR's stock was USD 210.23.
The most recent market capitalization for DHR is USD 148.68B.
Based on targets from 17 analysts, the average taret price for DHR is projected at USD 277.62 over the next 12 months.
This means that DHR's stock price may go up by +32.06% over the next 12 months.
We can't find any ETFs which contains Danaher Corporation's stock.
As per our most recent records Danaher Corporation has 61,000 Employees.
Danaher Corporation's registered address is 2200 Pennsylvania Avenue, North West, Washington, DC, United States, 20037-1701.
You can get more information about it from Danaher Corporation's website at https://www.danaher.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for DHR !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
